May 31, 2017 — BioVentrix Inc. recently announced the first clinical use of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System at the Deutsches Herzzentrum Berlin in Germany. The Less Invasive Ventricular Enhancement (LIVE) procedure was performed by interventional cardiologist Christoph Klein, M.D., and cardiothoracic surgeon Felix Hennig, M.D., with important contributions from Sebastian Kelle, M.D., chief of cardiovascular imaging.
The device was successfully implanted with two micro-anchor pairs in a 52-year-old male patient suffering from ischemic heart failure. The procedure reshaped the left ventricle and decreased the left ventricular end systolic volume index (LVESVI). Left ventricular volume reduction is a common measure of cardiac performance that significantly impacts the short and long-term survival rates. By remodeling the LV to a more normal shape and size, the implant improves pumping efficiency, decreases wall stress and immediately reverses patient symptoms.
"We are impressed by the immediate impact of the less-invasive Revivent TC system," said Kelle. "The patient achieved a 33 percent reduction in LVESVI and a 15 percent increase in the ejection fraction," he continued.
"The therapy provides a much-needed option for patients suffering from heart failure due to left ventricular anterior scar, particularly when medical therapy is no longer effective. We are impressed by the immediate improvements and are eager to learn about the long term results of this promising method," said Klein.
"This patient's quality of life was severely impacted by his heart failure," said Hennig. "Especially for an older and more fragile population, the risks and recovery of surgery often preclude any meaningful intervention. The LIVE procedure eliminates the invasive elements associated with conventional surgical reconstruction. It expands the patient population that will be able to benefit from this procedure," continued Hennig.
For more information: www.bioventrix.com
January 10, 2026 
